Acyclovir and transmission of HIV-1 from persons infected with HIV-1 and HSV-2

New England Journal of Medicine

Volumn 362, Issue 5, 2010, Pages 427-439

  Celum, Connie ^a   Wald, Anna ^a,c   Lingappa, Jairam R ^a,b   Magaret, Amalia S ^a,c   Wang, Richard S ^a   Mugo, Nelly ^a,e   Mujugira, Andrew ^a   Baeten, Jared M ^a   Mullins, James I ^a   Hughes, James P ^a   Bukusi, Elizabeth A ^a,e,f   Cohen, Craig R ^h   Katabira, Elly ⁱ   Ronald, Allan ^j   Kiarie, James ^e   Farquhar, Carey ^a   Stewart, Grace John ^a   Makhema, Joseph ^k   Essex, Myron ^l   Were, Edwin ^g   Fife, Kenneth H ^m   De Bruyn, Guy ⁿ   Gray, Glenda E ⁿ   McIntyre, James A ⁿ   Manongi, Rachel ^p   Kapiga, Saide ^p,q   Coetzee, David ^o   Allen, Susan ^r   Inambao, Mumbiana ^r   Kayitenkore, Kayitesi ^r   Karita, Etienne ^r   Kanweka, William ^r   Delany, Sinead ⁿ   Rees, Helen ⁿ   Vwalika, Bellington ^r   Stevens, Wendy ⁿ   Campbell, Mary S ^a   Thomas, Katherine K ^a   Coombs, Roberts W ^a   Morrow, Rhoda ^a   Whittington, William L H ^a   McElrath, M Juliana ^a,c   Barnes, Linda ^a   Ridzon, Renee ^d   Corey, Lawrence ^a,c   more..

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c Fred Hutchinson Cancer Research Center   (United States)

^d BILL AND MELINDA GATES FOUNDATION   (United States)

^e UNIVERSITY OF NAIROBI   (Kenya)

^f KENYA MEDICAL RESEARCH INSTITUTE   (Kenya)

^g MOI UNIVERSITY   (Kenya)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ MAKERERE UNIVERSITY   (Uganda)

^j UNIVERSITY OF MANITOBA   (Canada)

^k BOTSWANA HARVARD AIDS INSTITUTE PARTNERSHIP   (Botswana)

^l HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^m INDIANA UNIVERSITY   (United States)

ⁿ UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^o UNIVERSITY OF CAPE TOWN   (South Africa)

^p KILIMANJARO CHRISTIAN MEDICAL CENTRE   (Tanzania)

^q LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^r EMORY UNIVERSITY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; PLACEBO; VIRUS RNA;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFICACY; FEMALE; FOLLOW UP; GENE SEQUENCE; GENITAL ULCER; HERPES SIMPLEX; HERPES SIMPLEX VIRUS 2; HETEROSEXUALITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INFECTION CONTROL; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; SEQUENCE ANALYSIS; SEROCONVERSION; SERODIAGNOSIS; SEXUALITY; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VIRAL GENETICS; VIRUS REACTIVATION; VIRUS TRANSMISSION;

EID: 76149129743     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa0904849     Document Type: Article

References (33)

1. Weiss H. Epidemiology of herpes simplex virus type 2 infection in the developing world. Herpes 2004;11:Suppl 1:24A-35A.
2. Siegal FP, Lopez C, Hammer GS, et al. Severe acquired immunodeficiency in male homosexuals, manifested by chronic perianal ulcerative herpes simplex lesions. N Engl J Med 1981;305:1439-44.
3. Strick LB, Wald A, Celum C. Management of herpes simplex virus type 2 infection in HIV type 1-infected persons. Clin Infect Dis 2006;43:347-56.
4. Zuckerman RA, Lucchetti A, Whittington WL, et al. Herpes simplex virus (HSV) suppression with valacyclovir reduces rectal and blood plasma HIV-1 levels in HIV-1/HSV-2-seropositive men: a randomized, double-blind, placebo-controlled crossover trial. J Infect Dis 2007;196:1500-8.
5. Baeten JM, Strick LB, Lucchetti A, et al. Herpes simplex virus (HSV)-suppressive therapy decreases plasma and genital HIV-1 levels in HSV-2/HIV-1 coinfected women: a randomized, placebo-controlled, cross-over trial. J Infect Dis 2008;198: 1804-8.
6. Kucera LS, Leake E, Iyer N, Raben D, Myrvik QN. Human immunodeficiency virus type 1 (HIV-1) and herpes simplex virus type 2 (HSV-2) can coinfect and simultaneously replicate in the same human CD4+ cell: effect of coinfection on infectious HSV-2 and HIV-1 replication. AIDS Res Hum Retroviruses 1990;6:641-7.
7. Diaz JJ, Dodon MD, Schaerer-Uthurralt N, et al. Post-transcriptional transactivation of human retroviral envelope glycoprotein expression by herpes simplex virus Us11 protein. Nature 1996;379:273-7.
8. Heng MC, Heng SY, Allen SG. Co-infection and synergy of human immunodeficiency virus-1 and herpes simplex virus-1. Lancet 1994;343:255-8.
9. Mosca JD, Bednarik DP, Raj NB, et al. Herpes simplex virus type-1 can reactivate transcription of latent human immunodeficiency virus. Nature 1987;325:67-70.
10. Schacker T, Ryncarz AJ, Goddard J, Diem K, Shaughnessy M, Corey L. Frequent recovery of HIV-1 from genital herpes simplex virus lesions in HIV-1-infected men. JAMA 1998;280:61-6.
11. Schacker T, Zeh J, Hu H, Shaughnessy M, Corey L. Changes in plasma human immunodeficiency virus type 1 RNA associated with herpes simplex virus reactivation and suppression. J Infect Dis 2002;186:1718-25.
12. Mbopi-Kéou F-X, Grésenguet G, Mayaud P, et al. Interactions between herpes simplex virus type 2 and human immunodeficiency virus type 1 infection in African women: opportunities for intervention. J Infect Dis 2000;182:1090-6.
13. Baeten JM, McClelland RS, Corey L, et al. Vitamin A supplementation and genital shedding of herpes simplex virus among HIV-1-infected women: a randomized clinical trial. J Infect Dis 2004;189:1466-71.
14. Gray RH, Wawer MJ, Brookmeyer R, et al. Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1-discordant couples in Rakai, Uganda. Lancet 2001;357:1149-53.
15. Nagot N, Ouédraogo A, Foulongne V, et al. Reduction of HIV-1 RNA levels with therapy to suppress herpes simplex virus. N Engl J Med 2007;356:790-9.
16. Dunne EF, Whitehead S, Sternberg M, et al. Suppressive acyclovir therapy reduces HIV cervicovaginal shedding in HIV-and HSV-2-infected women, Chiang Rai, Thailand. J Acquir Immune Defic Syndr 2008;49:77-83.
17. Delany S, Mlaba N, Clayton T, et al. Impact of aciclovir on genital and plasma HIV-1 RNA in HSV-2/HIV-1 co-infected women: a randomized placebo-controlled trial in South Africa. AIDS 2009;23:461-9.
18. Lingappa JR, Kahle E, Mugo N, et al. Characteristics of HIV-1 discordant couples enrolled in a trial of HSV-2 suppression to reduce HIV-1 transmission: the Partners Study. PLoS One 2009;4(4):e5272.
19. Lan KKG, DeMets DL. Discrete sequential boundaries for clinical trials. Biometrika 1983;70:659-63.
20. O'Brien PC, Fleming TR. A multiple testing procedure for clinical trials. Biometrics 1979;35:549-56.
21. Laird NM, Ware JH. Random-effects models for longitudinal data. Biometrics 1982;38:963-74.
22. Glynn JR, Biraro S, Weiss HA. Herpes simplex virus type 2: a key role in HIV incidence. AIDS 2009;23:1595-8.
23. Cameron DW, Simonsen JN, D'Costa LJ, et al. Female to male transmission of human immunodeficiency virus type 1: risk factors for seroconversion in men. Lancet 1989;2:403-7.
24. Mole L, Ripich S, Margolis D, Holodniy M. The impact of active herpes simplex virus infection on human immunodeficiency virus load. J Infect Dis 1997;176:766-70.
25. Lisco A, Vanpouille C, Tchesnokov EP, et al. Acyclovir is activated into a HIV-1 reverse transcriptase inhibitor in herpes-virus-infected human tissues. Cell Host Microbe 2008;4:260-70.
26. McMahon MA, Siliciano JD, Lai J, et al. The antiherpetic drug acyclovir inhibits HIV replication and selects the V75I reverse transcriptase multidrug resistance mutation. J Biol Chem 2008;283:31289-93.
27. Gupta R, Wald A, Krantz E, et al. Valacyclovir and acyclovir for suppression of shedding of herpes simplex virus in the genital tract. J Infect Dis 2004;190:1374-81.
28. Walson JL, Otieno PA, Mbuchi M, et al. Albendazole treatment of HIV-1 and helminth co-infection: a randomized, double-blind, placebo-controlled trial. AIDS 2008;22:1601-9.
29. Gilbert PB, DeGruttola VG, Hudgens MG, Self SG, Hammer SM, Corey L. What constitutes efficacy for a human immunodeficiency virus vaccine that ameliorates viremia: issues involving surrogate end points in phase 3 trials. J Infect Dis 2003;188:179-93.
30. Dunkle KL, Stephenson R, Karita E, et al. New heterosexually transmitted HIV infections in married or cohabiting couples in urban Zambia and Rwanda: an analysis of survey and clinical data. Lancet 2008;371:2183-91.
31. Lingappa JR, Lambdin B, Bukusi EA, et al. Regional differences in prevalence of HIV-1 discordance in Africa and enrollment of HIV-1 discordant couples into an HIV-1 prevention trial. PLoS One 2008;3(1):e1411.
32. Quinn TC, Wawer MJ, Sewankambo N, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. N Engl J Med 2000;342:921-9.
33. Fideli US, Allen SA, Musonda R, et al. Virologic and immunologic determinants of heterosexual transmission of human immunodeficiency virus type 1 in Africa. AIDS Res Hum Retroviruses 2001;17:901-10.